Daily Treatment with SMTC1100, a Novel Small Molecule Utrophin Upregulator, Dramatically Reduces the Dystrophic Symptoms in the mdx Mouse
Figure 6
Effect of SMT C1100 on in vivo parameters of exercised mdx mice.
(A) Maximal fore limb strength after 4 weeks of either exercise and/or drug treatment. The values are mean ± SEM from the number of animals shown in each bar (B) Normalized force increment, i.e. difference between the mean values of normalized fore limb strength at time 4 and at time 0. Normalized force values have been calculated for each mouse as the ratio of maximal fore limb strength to mouse body weight. The values are mean ± SE. The SE of ΔNF has been calculated as detailed elsewhere [14], [21]. For (A) and (B) statistical significance between groups was evaluated by ANOVA test for multiple comparison (F-values) and Bonferroni t-test post hoc correction. Significantly different versus *sedentary mdx and §Exer mdx; p<0.05; (C) Resistance to treadmill running, calculated as the maximal distance the mouse can run when undergoing a single bout of treadmill exercise. The values are mean ± SEM from 3–7 mice and show the maximal distance run (in meters) at T0 (start of forced exercise and dosing) and after four (T4) and five weeks (T5). Statistical significance between groups was evaluated by ANOVA test for multiple comparison (F-values) and Bonferroni t-test post hoc correction. Highly significant differences were observed between groups and within groups at the different ages (F>10; p<0.005). The symbols show statistical differences *versus sedentary mdx at T4 and #versus vehicle-treated exercised mdx at either T4 or T5 (p<0.05 and less).